FDA Approves New Dosage of Trastuzumab Biosimilar for HER2 ...
WEB1 day ago · The agent is approved to treat HER2-overexpressing cancers. In April 2024, the FDA approved the 150-mg dose of trastuzumab-strf. Trastuzumab-strf, a trastuzumab biosimilar, at 420 mg has been approved by the FDA for the treatment of HER2-overexpressing cancers, including metastatic breast …
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
WEBJul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2-targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.
FDA Approves First Targeted Drug To Treat HER2-Low Breast …
WEBJun 5, 2022 · Trastuzumab (Herceptin®) was the first targeted therapy developed to treat HER2-positive patients. “HER2-positive,” which accounts for 15% to 20% of all breast cancers, means there is a high level of the HER2 protein on the surface of cancer cells, driving tumor growth.
Targeting HER2-positive breast cancer: advances and future …
WEBNov 7, 2022 · The dependence of the tumour on HER2, coupled with effective HER2-targeted drugs such as trastuzumab, pertuzumab and most recently, tucatinib and trastuzumab deruxtecan (T-DXd), have...
FDA grants accelerated approval to fam-trastuzumab deruxtecan …
WEBOn April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or...
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed …
WEBSep 13, 2024 · fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for …
WEBMar 23, 2022 · Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated with trastuzumab and a taxane, as well as with ...
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
WEBJun 7, 2022 · Two-thirds took the experimental drug, trastuzumab deruxtecan, sold as Enhertu; the rest underwent standard chemotherapy. In patients who took trastuzumab deruxtecan, tumors stopped growing for...
Skip to content